Spruce Biosciences jumps as co moves toward FDA filing for rare childhood brain disorder drug

Shares of drug developer Spruce Biosciences SPRB.O rise 27% to $74 premarket

 Co says its therapy targets Sanfilippo Syndrome Type B, a rare genetic disorder that causes progressive brain damage and loss of motor skills in children

Co says FDA confirmed its existing clinical data could support an accelerated review of its experimental enzyme‑replacement therapy

  Co says the treatment aims to replace a missing enzyme to slow or halt disease progression

  Co says the drug has been tested in 22 patients over six years with a favorable safety profile

SPRB says it expects to file its application in Q4 2026 after completing FDA manufacturing requirements

Shares up ~177% in 2025